EX-10.3
from 10-Q
13 pages
Contains Confidential Business Information via Electronic Mail Victor Rivera Vicrivera@me.com Dear Vic: As Discussed, Your Employment With Theseus Pharmaceuticals, Inc. (The “Company”) Will Terminate on November 9, 2023. a Copy of Your Separation and Release Agreement Is Enclosed With This Letter. Please Note That the Termination of Your Employment Is an “Involuntary Termination”, Which Qualifies You for Certain “Severance Benefits” as Set Forth in Your Offer Letter. While the Company’s Proposed Transaction Does Not Meet the Criteria for a “Change in Control” Under the Terms of Your Offer Letter, the Company Is Pleased to Provide You With Severance Benefits Beyond Those Set Forth in Section 5(a)(i) of Your Offer Letter as a Recognition of Your Contributions to the Company. Specifically, in Addition to Those Benefits Set Forth in Sections 5(a)(i) and 5(b) of Your Offer Letter, You Will Receive Your Annual Target Bonus, Prorated Through Your Last Day, as Well as Acceleration of Your Equity Awards That Would Have Vested Over the Twelve (12) Period From Your Last Day. Thank You for All You Have Done at the Company, and We Wish You Continued Success. [Signature Page to Follow] Regards, Theseus Pharmaceuticals, Inc. By: /S/ Brad Dahms Brad Dahms CFO
12/34/56
